Unlimited Bio will test a combination therapy with Neovasculgen

Unlimited Bio has published data on the start of research in Honduras on a combined gene therapy using the gene therapy drug Neovasculgen from the biotech company Nextgen. Purpose of the study is to investigate the safety of using Neovasculgen in combination with gene therapy with the Follistatin gene to prevent age-related loss of muscle mass in healthy individuals aged 45-75 years. Study will be conducted on 12 volunteers and will continue until 2028.